Please login to the form below

Not currently logged in
Email:
Password:

SD-809

This page shows the latest SD-809 news and features for those working in and with pharma, biotech and healthcare.

FDA sets August review date for Teva's movement disorder drug

FDA sets August review date for Teva's movement disorder drug

Patients with the movement disorder tardive dyskinesia (TD) could have a first approved treatment if the FDA clears Teva's SD-809 candidate later this year. ... Teva needs that kind of return, having forked out $3.5bn for SD-809's developer Auspex Pharma

Latest news

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    Teva's drug SD 809 for the treatment of Huntington's disease was part of the acquisition of Auspex at a cost of $3.5bn. ... Originally reported in DW Issue 57 [March 2015], Teva paid a 42% premium to acquire the company, which included other pipeline

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics